KR20220164751A - Tyk2 억제제의 결정질 형태 - Google Patents
Tyk2 억제제의 결정질 형태 Download PDFInfo
- Publication number
- KR20220164751A KR20220164751A KR1020227038120A KR20227038120A KR20220164751A KR 20220164751 A KR20220164751 A KR 20220164751A KR 1020227038120 A KR1020227038120 A KR 1020227038120A KR 20227038120 A KR20227038120 A KR 20227038120A KR 20220164751 A KR20220164751 A KR 20220164751A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- mixture
- hours
- crystalline form
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005114.0A GB202005114D0 (en) | 2020-04-07 | 2020-04-07 | Crystalline Forms of a Pharmaceutical Compound |
| GB2005114.0 | 2020-04-07 | ||
| PCT/EP2021/058864 WO2021204762A1 (en) | 2020-04-07 | 2021-04-06 | Crystalline forms of a tyk2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220164751A true KR20220164751A (ko) | 2022-12-13 |
Family
ID=70768933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227038120A Pending KR20220164751A (ko) | 2020-04-07 | 2021-04-06 | Tyk2 억제제의 결정질 형태 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12545652B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4132649A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7660135B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220164751A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115515683B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022016359A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3167172A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202005114D0 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296989A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022011593A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021204762A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| JP2025510826A (ja) * | 2022-03-25 | 2025-04-15 | 武田薬品工業株式会社 | Tyk2阻害剤の固体形態及び使用方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
| GB1497536A (en) | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| JPH0753716B2 (ja) | 1986-07-02 | 1995-06-07 | 吉富製薬株式会社 | イミダゾ−ルカルボキサミド誘導体 |
| DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| BR0111754A (pt) | 2000-06-28 | 2003-04-29 | Astrazeneca Ab | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica |
| AU2479702A (en) | 2000-10-30 | 2002-05-15 | Janssen Pharmaceutica Nv | Tripeptidyl peptidase inhibitors |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| ATE465731T1 (de) | 2003-10-23 | 2010-05-15 | Ab Science | 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| CA2623327A1 (en) | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| WO2007131953A1 (en) | 2006-05-12 | 2007-11-22 | Ab Science | A new process for the synthesis of 2-aminoxazole compounds |
| US20090093452A1 (en) | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| US8367706B2 (en) | 2007-06-20 | 2013-02-05 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2278969B1 (en) | 2008-04-21 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| EP2299816B1 (en) | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2310384B1 (en) | 2008-07-09 | 2014-04-09 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| US20130143915A1 (en) | 2010-07-01 | 2013-06-06 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| SG11201401342VA (en) | 2011-10-12 | 2014-09-26 | Array Biopharma Inc | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| ES2566205T3 (es) | 2012-03-02 | 2016-04-11 | Sareum Limited | Inhibidores de quinasa TYK2 |
| KR101202026B1 (ko) | 2012-07-03 | 2012-11-16 | 민호현 | 황토 석부작 제조 방법 |
| HRP20220766T1 (hr) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| BR112016004723B1 (pt) * | 2013-09-03 | 2022-08-30 | Sareum Limited | Compostos de pirrolidina ou morfolina e composição contendo os mesmos |
| NO2721710T3 (cg-RX-API-DMAC7.html) | 2014-08-21 | 2018-03-31 | ||
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
-
2020
- 2020-04-07 GB GBGB2005114.0A patent/GB202005114D0/en not_active Ceased
-
2021
- 2021-04-06 IL IL296989A patent/IL296989A/en unknown
- 2021-04-06 BR BR112022016359A patent/BR112022016359A2/pt unknown
- 2021-04-06 MX MX2022011593A patent/MX2022011593A/es unknown
- 2021-04-06 WO PCT/EP2021/058864 patent/WO2021204762A1/en not_active Ceased
- 2021-04-06 JP JP2022559959A patent/JP7660135B2/ja active Active
- 2021-04-06 EP EP21717041.4A patent/EP4132649A1/en active Pending
- 2021-04-06 US US17/905,183 patent/US12545652B2/en active Active
- 2021-04-06 CN CN202180025999.3A patent/CN115515683B/zh active Active
- 2021-04-06 KR KR1020227038120A patent/KR20220164751A/ko active Pending
- 2021-04-06 CA CA3167172A patent/CA3167172A1/en active Pending
-
2026
- 2026-01-06 US US19/440,870 patent/US20260217664A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021253128A1 (en) | 2022-08-25 |
| GB202005114D0 (en) | 2020-05-20 |
| JP7660135B2 (ja) | 2025-04-10 |
| EP4132649A1 (en) | 2023-02-15 |
| MX2022011593A (es) | 2022-10-18 |
| CA3167172A1 (en) | 2021-10-14 |
| US20230159473A1 (en) | 2023-05-25 |
| IL296989A (en) | 2022-12-01 |
| BR112022016359A2 (pt) | 2022-10-04 |
| CN115515683A (zh) | 2022-12-23 |
| WO2021204762A1 (en) | 2021-10-14 |
| CN115515683B (zh) | 2024-10-25 |
| US20260217664A1 (en) | 2026-07-30 |
| US12545652B2 (en) | 2026-02-10 |
| JP2023521631A (ja) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11673870B2 (en) | Pharmaceutical compounds | |
| JP6239118B2 (ja) | 医薬化合物 | |
| JP7660135B2 (ja) | Tyk2阻害剤の結晶形態 | |
| JP7383030B2 (ja) | Tyk2キナーゼ阻害剤 | |
| RU2805932C2 (ru) | Фармацевтические соединения | |
| HK40048146A (en) | Tyk2 kinase inhibitors | |
| HK40048146B (en) | Tyk2 kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |